Abstract
This article provides information and commentaries on trials which were presented at Clinical Trial Updates and Hotline Sessions presented at the Scientific Sessions 2007 of the American Heart Association in Orlando, Florida. The comprehensive summaries have been generated from the oral presentations and the webcasts of the American Heart Association. Most reports have not been published as full papers and therefore have to be considered as preliminary data, as the analysis may change in the final publications. The following papers are discussed: TRITON TIMI-38, EVA-AMI, BRIEF-PCI, RACE, MASS Stent, HF-ART, STITCH, CORONA, ILLUMINATE, CORE-64, OAT Substudy, AFCHF, MASCOT, RETHINQ, MASTER I, POISE, COUMA-GEN, HIJ-CREATE, PROVIDENCE I, CAUSMIC, IC-BMC, IC/IM BMCs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bassand JP, Hamm CW, Ardissino D et al (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28:1598–1660
Schuler J, Maier B, Behrens S et al (2006) Present treatment of acute myocardial infarction in patients over 75 years–data from the Berlin Myocardial Infarction Registry (BHIR). Clin Res Cardiol 95:360–367
Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 357:2001–2015
Montalescot G, Antoniucci D, Kastrati A et al (2007) Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients’ data with long-term follow-up. Eur Heart J 28:443–449
Schroder K, Wegscheider K, Zeymer U et al (2001) Extent of ST-segment deviation in a single electrocardiogram lead 90 min after thrombolysis as a predictor of medium-term mortality in acute myocardial infarction. Lancet 358:1479–1486
O'Shea JC, Hafley GE, Greenberg S et al (2001) Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 285:2468–2473
Böhm M, Werner N, Kindermann M (2006) Drug treatment of chronic heart failure. Clin Res Cardiol 95 (Suppl 4):36–54
Laufs U, Custodis F, Böhm M (2006) HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk. Drugs 66:145–154
Kjekshus J, Apetrei E, Barrios V et al (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248–2261
Rupprecht HJ (2006) Cardiovascular secondary prevention. Clin Res Cardiol 95 (Suppl 6):VI1–VI5
Luley C (2006) Lipometabolic disorder- cholesterol and triglycerides. Clin Res Cardiol 95 (Suppl 6):VI17–VI22
Genser B, Marz W (2006) Low density lipoprotein cholesterol, statins and cardiovascular events: a metaanalysis. Clin Res Cardiol 95:393–404
Barter PJ, Caulfield M, Eriksson M et al (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109–2122
Hochman JS, Lamas GA, Buller CE et al (2006) Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 355:2395– 407
Gotze S, Butter C, Fleck E (2006) Cardiac resynchronization therapy for heart failure – from experimental pacing to evidence-based therapy. Clin Res Cardiol 95 (Suppl 4):18–33
Trappe HJ (2006) New perspective in arrhythmia and heart failure monitoring. Clin Res Cardiol 95 (Suppl 3):III1–III2
Aidelsburger P, Grabein K, Klauss V et al (2007) Cost-effectiveness of cardiac resynchronization therapy in combination with an implantable cardioverter defibrillator (CRT-D) for the treatment of chronic heart failure froma German health care systemperspective. Clin Res Cardiol (epub ahead of print)
Beshai JF, Grimm RA, Nagueh SF et al (2007) Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med (epub ahead of print)
Wollert KC, Meyer GP, Lotz J et al (2004) Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364:141–148
Schächinger V, Erbs S, Elsasser A et al (2006) Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 27:2775–2783
Schächinger V, Assmus B, Honold J et al (2006) Normalization of coronary blood flow in the infarct-related artery after intracoronary progenitor cell therapy: intracoronary Doppler substudy of the TOPCARE-AMI trial. Clin Res Cardiol 95:13–22
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Laufs, U., Nef, H., Möllmann, H. et al. Clinical Trial Updates and Hotline Sessions presented at the Scientific Session 2007 of the American heart association. Clin Res Cardiol 97, 1–11 (2008). https://doi.org/10.1007/s00392-008-0625-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-008-0625-1